Skip to content
Bomb Report – Lifestyle
Author:
Moderna, Inc.
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
April 7, 2026
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
March 6, 2026
European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
March 6, 2026
←
Previous Page
1
2
3